Autoantistoffer mod koagulationsfaktor VIII

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Autoantistoffer mod koagulationsfaktor VIII. / Friis-Hansen, Lennart J.; Andersen, Niels Smedegaard; Scheibel, Elma.

In: Ugeskrift for Laeger, Vol. 160, No. 42, 12.10.1998, p. 6061-6065.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Friis-Hansen, LJ, Andersen, NS & Scheibel, E 1998, 'Autoantistoffer mod koagulationsfaktor VIII', Ugeskrift for Laeger, vol. 160, no. 42, pp. 6061-6065.

APA

Friis-Hansen, L. J., Andersen, N. S., & Scheibel, E. (1998). Autoantistoffer mod koagulationsfaktor VIII. Ugeskrift for Laeger, 160(42), 6061-6065.

Vancouver

Friis-Hansen LJ, Andersen NS, Scheibel E. Autoantistoffer mod koagulationsfaktor VIII. Ugeskrift for Laeger. 1998 Oct 12;160(42):6061-6065.

Author

Friis-Hansen, Lennart J. ; Andersen, Niels Smedegaard ; Scheibel, Elma. / Autoantistoffer mod koagulationsfaktor VIII. In: Ugeskrift for Laeger. 1998 ; Vol. 160, No. 42. pp. 6061-6065.

Bibtex

@article{676bcbfe141842dea0122e965a4a8c89,
title = "Autoantistoffer mod koagulationsfaktor VIII",
abstract = "Autoantibodies towards coagulation factor VIII is a rare disease, incidence 1 pr. 2.5-5 million/year. The symptoms are most often subcutaneous or intramuscular haemorrhages or uncontrollable bleeding after minimal traumas. Screening tests show prolonged activated partial thromboplastin time, normal prothrombin time and thrombocyte count. Production of autoantibodies is controlled by prednisolone which may be supplemented with chemotherapy, ie. azathioprine. Bleeding can be controlled by using coagulation factor concentrates that bypass factor VIII. If diagnosed early, there is a good chance of both stopping bleeding and suppressing autoantibody production. In order to be able to detect patients at risk of having factor VIII autoantibodies, it is recommended to screen all bleeding patients using activated partial thromboplastin time, prothrombin time and thrombocyte count. All patients showing isolated prolonged activated partial thrombin time should be referred to a laboratory specialized in coagulation problems for immediate evaluation.",
author = "Friis-Hansen, {Lennart J.} and Andersen, {Niels Smedegaard} and Elma Scheibel",
year = "1998",
month = oct,
day = "12",
language = "Dansk",
volume = "160",
pages = "6061--6065",
journal = "Ugeskrift for Laeger",
issn = "0041-5782",
publisher = "Almindelige Danske Laegeforening",
number = "42",

}

RIS

TY - JOUR

T1 - Autoantistoffer mod koagulationsfaktor VIII

AU - Friis-Hansen, Lennart J.

AU - Andersen, Niels Smedegaard

AU - Scheibel, Elma

PY - 1998/10/12

Y1 - 1998/10/12

N2 - Autoantibodies towards coagulation factor VIII is a rare disease, incidence 1 pr. 2.5-5 million/year. The symptoms are most often subcutaneous or intramuscular haemorrhages or uncontrollable bleeding after minimal traumas. Screening tests show prolonged activated partial thromboplastin time, normal prothrombin time and thrombocyte count. Production of autoantibodies is controlled by prednisolone which may be supplemented with chemotherapy, ie. azathioprine. Bleeding can be controlled by using coagulation factor concentrates that bypass factor VIII. If diagnosed early, there is a good chance of both stopping bleeding and suppressing autoantibody production. In order to be able to detect patients at risk of having factor VIII autoantibodies, it is recommended to screen all bleeding patients using activated partial thromboplastin time, prothrombin time and thrombocyte count. All patients showing isolated prolonged activated partial thrombin time should be referred to a laboratory specialized in coagulation problems for immediate evaluation.

AB - Autoantibodies towards coagulation factor VIII is a rare disease, incidence 1 pr. 2.5-5 million/year. The symptoms are most often subcutaneous or intramuscular haemorrhages or uncontrollable bleeding after minimal traumas. Screening tests show prolonged activated partial thromboplastin time, normal prothrombin time and thrombocyte count. Production of autoantibodies is controlled by prednisolone which may be supplemented with chemotherapy, ie. azathioprine. Bleeding can be controlled by using coagulation factor concentrates that bypass factor VIII. If diagnosed early, there is a good chance of both stopping bleeding and suppressing autoantibody production. In order to be able to detect patients at risk of having factor VIII autoantibodies, it is recommended to screen all bleeding patients using activated partial thromboplastin time, prothrombin time and thrombocyte count. All patients showing isolated prolonged activated partial thrombin time should be referred to a laboratory specialized in coagulation problems for immediate evaluation.

UR - http://www.scopus.com/inward/record.url?scp=0032511659&partnerID=8YFLogxK

M3 - Tidsskriftartikel

C2 - 9800508

AN - SCOPUS:0032511659

VL - 160

SP - 6061

EP - 6065

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

SN - 0041-5782

IS - 42

ER -

ID: 310765909